Aspireo Pharmaceuticals Limited
5 clinical trials · Sponsor
◉ Watch Aspireo Pharmaceuticals Limited
| Record | Firm | Date |
|---|---|---|
| The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics (NCT02217800) | Aspireo Pharmaceuticals Limited | 2013-11-01 |
| Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients. (NCT02235987) | Aspireo Pharmaceuticals Limited | 2012-10-01 |
| Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173 (NCT02217839) | Aspireo Pharmaceuticals Limited | 2012-04-01 |
| Single Ascending Dose Tolerability Study of DG3173 (NCT02217488) | Aspireo Pharmaceuticals Limited | 2008-05-01 |
| Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173 (NCT02217826) | Aspireo Pharmaceuticals Limited |
Track Aspireo Pharmaceuticals Limited automatically
Every clearance here is in the API, with alerts when new ones post.